SCHEMBL2233032

SCHEMBL2233032

COc1ccc(Nc2nc(-c3cc(OC)c(OC)c(OC)c3)nc3ccccc23)cc1

nearest known ligand 0.78

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.78
ABCG2 Q9UNQ0 12/20 0.76
MEN1 O00255 7/20 0.74
KMT2A Q03164 7/20 0.74
ABCB1 P08183 5/20 0.72
ABCC1 P33527 4/20 0.72
MAPT P10636 3/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
TP53 P04637 1/20 0.67
NPC1 O15118 1/20 0.63
KDM4E B2RXH2 1/20 0.61
LMNA P02545 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
ATM Q13315 1/20 0.61
GAA P10253 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2232737 0.93 KDM1A (0.81) KDM1AABCG2MEN1KMT2AABCB1
SCHEMBL2232368 0.91 KDM1A (0.78) KDM1AABCG2MEN1KMT2AABCB1
SCHEMBL16404472 0.90 ABCG2 (0.87) KDM1AABCG2MEN1KMT2AABCB1
SCHEMBL2232116 0.90 ABCG2 (0.81) KDM1AABCG2MEN1KMT2AABCB1
SCHEMBL2231161 0.90 KDM1A (0.77) KDM1AABCG2MEN1KMT2AABCB1
SCHEMBL2232337 0.89 KDM1A (0.70) KDM1AABCG2MEN1KMT2AABCB1
SCHEMBL16404294 0.88 ABCG2 (0.86) KDM1AABCG2MEN1KMT2AABCB1
SCHEMBL16404494 0.86 ABCG2 (0.95) KDM1AABCG2MEN1KMT2AABCB1
SCHEMBL1064726 0.86 ABCG2 (1.00) KDM1AABCG2MEN1KMT2AABCB1
SCHEMBL2230833 0.86 KDM1A (0.65) KDM1AABCG2MEN1KMT2AABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528606-B1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS LEVITZKI ALEXANDER (IL) 2014-09-24 EP disclosed
US-8759363-B2 Quinazoline-based T cell proliferation inhibitors YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2014-06-24 US disclosed
US-20130109706-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSALEM LTD. (IL) 2013-05-02 US disclosed
EP-2528606-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) 2012-12-05 EP disclosed
WO-2011092695-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109706-A1 QUINAZOLINE-BASED T CELL PROLIFERATION INHIBITORS IL2, CD4, NFATC1 KDM1A 2957/4885ABCG2 2405/4885MEN1 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.